Preterm Birth Diagnostic Test Kits Market Size & Growth Forecast 2027–2036, By Segments (Sample Type, End-use, Product Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Preterm Birth Diagnostic Test Kits Market size was worth USD 536.07 Million in 2026 and is expected to grow at 7.84% CAGR between 2027 and 2036, reaching USD 1.14 Billion by 2036. The industry revenue for 2027 is assessed at USD 571.77 Million.
Get more details on this report
Request Free Sample ReportPreterm Birth Diagnostic Test Kits Market Intelligence Snapshot
Regional Market Dynamics
- North America led in 2026, supported by well-developed maternal healthcare infrastructure, advanced diagnostics, prenatal screening adoption, and strong clinical awareness of preterm birth risks.
- Asia Pacific is expected to grow fastest as healthcare infrastructure, maternal health awareness, prenatal diagnostic access, and investments in advanced healthcare facilities expand.
Segment Momentum
- The blood sample segment dominated with a 42.93% share in 2026, supported by integration into clinical workflows, biomarker advancements, and growing demand for early pregnancy risk assessment.
- Diagnostic centers accounted for 45.58% in 2026 and are expanding rapidly due to specialized testing infrastructure, increased prenatal screening referrals, and demand for timely pregnancy risk detection.
Market Expansion Drivers
- Increasing incidence of preterm births driving demand for early and accurate diagnostic screening kits
- Expanding neonatal intensive care infrastructure improving early detection and intervention capabilities
- Rising development of advanced biomarker-based diagnostics improving prediction accuracy for preterm labor risk
Leading Market Participants
- Prominent players in the preterm birth diagnostic test kits market include Abbott Laboratories (United States), Hologic, Inc. (United States), QIAGEN N.V. (Netherlands), CooperSurgical, Inc. (United States), Sera Prognostics, Inc. (United States), Clinical Innovations, LLC (United States), Biosynex S.A. (France), Medix Biochemica Oy (Finland), Creative Diagnostics (United States), Thermo Fisher Scientific Inc. (United States)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 536.07 Million
- 2027 Estimated Market Size: USD 571.77 Million
- Projected Market Size: USD 1.14 Billion by 2036
- Growth Forecast: 7.84% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Blood Sample (Sample Type) | Diagnostic Centers (End-use) | Fetal Fibronectin Test Kits (fFN) (Product Type)
- Emerging Opportunity Segment: Blood Sample (Sample Type) | Diagnostic Centers (End-use) | Fetal Fibronectin Test Kits (fFN) (Product Type)
Market Growth Drivers and Industry Trends
Increasing incidence of preterm births driving demand for early and accurate diagnostic screening kits
A rising number of pregnancies at risk of premature delivery has intensified the need for diagnostic tools capable of identifying complications before the onset of labor. The preterm birth diagnostic test kits market will boost demand as healthcare providers increasingly adopt early screening approaches that support timely clinical decision-making and individualized maternal care. Earlier identification of women at elevated risk enables physicians to implement appropriate monitoring strategies, optimize treatment planning, and better manage pregnancies that require closer medical supervision.
Expanding neonatal intensive care infrastructure improving early detection and intervention capabilities
Healthcare systems are strengthening neonatal care capacity by expanding specialized facilities equipped to manage high-risk pregnancies and premature infants. This ongoing investment will propel the preterm birth diagnostic test kits market because advanced neonatal intensive care environments increasingly integrate diagnostic screening into comprehensive maternal and fetal care pathways. Improved coordination between obstetric teams, diagnostic laboratories, and neonatal specialists encourages earlier risk assessment while supporting more informed clinical interventions before delivery.
Rising development of advanced biomarker-based diagnostics improving prediction accuracy for preterm labor risk
Research focused on novel biomarkers is enhancing the ability of diagnostic technologies to identify biological changes associated with preterm labor before clinical symptoms become apparent. The preterm birth diagnostic test kits market is benefiting from these advances as more sophisticated testing approaches improve predictive performance, helping clinicians distinguish high-risk pregnancies with greater confidence. Enhanced diagnostic precision also supports personalized patient management by enabling more targeted monitoring strategies and reducing uncertainty during prenatal risk evaluation.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing incidence of preterm births driving demand for early and accurate diagnostic screening kits | 2.3% | High | North America, Europe, Asia Pacific | High | Near Term |
| Expanding neonatal intensive care infrastructure improving early detection and intervention capabilities | 2% | High | North America, Europe | High | Near Term |
| Rising development of advanced biomarker-based diagnostics improving prediction accuracy for preterm labor risk | 1.7% | High | North America, Asia Pacific | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
The preterm birth diagnostic test kits market was led by North America, which held the largest share in 2026. The region benefits from well-developed maternal healthcare infrastructure, broader access to advanced diagnostic technologies, and strong clinical awareness surrounding the early identification of preterm birth risks. Established healthcare systems and greater adoption of prenatal screening and diagnostic procedures support demand for reliable testing solutions. In addition, ongoing emphasis on improving maternal and neonatal outcomes encourages healthcare providers to incorporate timely diagnostic approaches into prenatal care, strengthening the region's market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to register the fastest growth over the forecast period, supported by expanding healthcare infrastructure, rising awareness of maternal and neonatal health, and improving access to prenatal diagnostic services. Growing investments in healthcare facilities across emerging economies are increasing the availability of advanced diagnostic technologies beyond major urban centers. At the same time, efforts to reduce pregnancy-related complications and improve early detection of high-risk pregnancies are encouraging greater use of diagnostic test kits, creating favorable opportunities for market expansion across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Maternal Risk AssessmentThe U.S. promotes preterm birth diagnostic test kits that support earlier identification of pregnancy-related complications. Healthcare providers increasingly incorporate diagnostic testing into prenatal care pathways to improve clinical decision-making.
Germany 🇩🇪
Evidence-Based Prenatal TestingGermany emphasizes clinically validated preterm birth diagnostic test kits within specialist obstetric care. Diagnostic providers focus on reliable biomarker performance and integration with standardized maternal health management protocols.
Japan 🇯🇵
Early Pregnancy MonitoringJapan supports wider adoption of preterm birth diagnostic test kits through structured prenatal monitoring programs. Clinical laboratories prioritize accurate testing methods that assist physicians in identifying higher-risk pregnancies at earlier stages.
South Korea 🇰🇷
Diagnostic Innovation AdoptionSouth Korea continues incorporating innovative preterm birth diagnostic test kits into maternal healthcare services. Hospitals emphasize rapid, dependable diagnostic solutions that strengthen pregnancy risk assessment and timely clinical intervention.
France 🇫🇷
Obstetric Care EnhancementFrance integrates preterm birth diagnostic test kits into comprehensive prenatal care for women with elevated pregnancy risks. Healthcare providers focus on improving diagnostic confidence and supporting individualized maternal care planning.
Italy 🇮🇹
Prenatal Screening ExpansionItaly expands the use of preterm birth diagnostic test kits within obstetric clinics to improve early pregnancy assessment. Clinical priorities include dependable testing performance, timely diagnosis, and effective integration into routine prenatal care pathways.
Segment Leadership and Growth Trends
Preterm Birth Diagnostic Test Kits Market Share (%), by Sample Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportSample Type Segment Analysis: Blood Sample (Largest & Fastest-Growing Segment)
The blood sample segment dominated the preterm birth diagnostic test kits market with a 42.93% share in 2026 while also emerging as the fastest-growing sample type. Blood-based testing is widely utilized because it integrates easily into routine clinical workflows and provides healthcare professionals with valuable diagnostic information for assessing the risk of preterm birth. Ongoing advancements in biomarker identification, increasing adoption of minimally invasive diagnostic techniques, and growing emphasis on early pregnancy risk assessment continue to strengthen the segment's leading position.
End-use Segment Analysis: Diagnostic Centers (Largest & Fastest-Growing Segment)
In the preterm birth diagnostic test kits market, the diagnostic centers segment accounted for 45.58% in 2026 while also representing the fastest-growing end-use category. Diagnostic centers are equipped with specialized laboratory infrastructure and trained personnel capable of delivering accurate and timely testing services. Increasing referrals for prenatal screening, expanding access to specialized maternal healthcare diagnostics, and the growing importance of early detection in pregnancy management are reinforcing the segment's leadership and sustained expansion.
Product Type Segment Analysis: Fetal Fibronectin Test Kits (fFN) (Largest & Fastest-Growing Segment)
Holding the largest share of the preterm birth diagnostic test kits market, the fetal fibronectin test kits (fFN) segment remained the dominant product type in 2026 while also being the fastest-growing segment. These test kits are widely used to help evaluate the likelihood of preterm labor by supporting timely clinical assessment and informed treatment decisions. Their established role in obstetric care, increasing emphasis on reducing unnecessary hospital admissions, and growing awareness of early risk identification continue to drive widespread adoption across maternal healthcare settings.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Sample Type | Blood Sample, Urine Sample, Vaginal Discharge Sample | Blood Sample | Blood Sample |
| End-use | Hospitals, Diagnostic Centers, Clinics, Others | Diagnostic Centers | Diagnostic Centers |
| Product Type | Fetal Fibronectin Test Kits (fFN), Placental Alpha Micro-Globulin-1 Test Kits (PAMG-1), Insulin Like Growth Factor Binding Protein-1 Test Kits (IGFBP-1), Others | Fetal Fibronectin Test Kits (fFN) | Fetal Fibronectin Test Kits (fFN) |
Competitive Landscape and Market Positioning
Top players in the preterm birth diagnostic test kits market:
- Abbott Laboratories (United States)
- Hologic, Inc. (United States)
- QIAGEN N.V. (Netherlands)
- CooperSurgical, Inc. (United States)
- Sera Prognostics, Inc. (United States)
- Clinical Innovations LLC (United States)
- Biosynex S.A. (France)
- Medix Biochemica Oy (Finland)
- Creative Diagnostics (United States)
- Thermo Fisher Scientific, Inc. (United States)
Competition in the preterm birth diagnostic test kits market is being driven by efforts to improve early risk identification, clinical confidence, and ease of use within maternal healthcare settings. Market participants are differentiating through advancements in diagnostic accuracy, testing convenience, and integration into existing clinical workflows. As healthcare providers seek better tools for proactive intervention, competitive positioning is becoming increasingly dependent on the ability to deliver reliable insights while supporting broader adoption among care providers.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| Hologic Inc. (United States) | |||||||
| QIAGEN N.V. (Netherlands) | |||||||
| CooperSurgical Inc. (United States) | |||||||
| Sera Prognostics Inc. (United States) | |||||||
| Clinical Innovations LLC (United States) | |||||||
| Biosynex S.A. (France) | |||||||
| Medix Biochemica Oy (Finland) | |||||||
| Creative Diagnostics (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Sera Prognostics | Mar-26 | Sera Prognostics reported full-year 2025 financial results alongside ongoing commercial expansion initiatives, highlighting active reimbursement discussions with commercial and Medicaid plans and expanded U.S. sales operations targeting integrated delivery networks. |
| Sera Prognostics | Jan-26 | Sera Prognostics published the PRIME randomized controlled trial evaluating its PreTRM blood test combined with targeted interventions, demonstrating a 56% reduction in births before 32 weeks and a 20% decrease in neonatal intensive care unit admissions across 5,018 patients at 19 U.S. clinical sites. |
| Roche Diagnostics | Feb-25 | Roche Diagnostics secured U.S. Food and Drug Administration 510(k) clearance for its Elecsys sFlt-1/PlGF ratio prognostic test, designed to stratify hospitalized pregnant women with hypertensive disorders by short-term risk of developing severe preeclampsia. |
| Medix Biochemica | Jun-21 | Medix Biochemica launched 'MedixMDx', a dedicated molecular diagnostic reagents division structured to supply a broad portfolio of products and services to the diagnostic assay development sector. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Preterm Birth Diagnostic Test Kits Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Gestational Age at Testing | Less Than 28 Weeks, 28–32 Weeks, 33–36 Weeks, 37 Weeks and Above |
| Clinical Use Case | Preterm Labor Risk Assessment, Ruptured Membrane Assessment, Preterm Birth Risk Prediction, Emergency Obstetric Evaluation |
| Distribution Channel | Direct Sales, Hospital & Healthcare Procurement, Medical Distributors, Online & Specialty Diagnostic Suppliers |
Preterm Birth Diagnostic Test Kits Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Clinical Adoption and Diagnostic Pathways |
|
| Reimbursement and Economic Value Assessment |
|
| Point-of-Care Testing Expansion |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of preterm birth diagnostic test kits?
How is the preterm birth diagnostic test kits industry size expected to evolve during the forecast period?
How is demand for early pregnancy risk assessment accelerating adoption of preterm birth diagnostic kits?
How are biomarker-based diagnostic advancements influencing the future of preterm birth testing?
Why does the blood sample segment lead the preterm birth diagnostic test kits market?
How are diagnostic centers driving growth in the preterm birth diagnostic test kits market?
Why does North America lead the preterm birth diagnostic test kits market?
How is Asia Pacific driving future market growth?
Which companies dominate the preterm birth diagnostic test kits landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization